Targeting Interleukin-4 Receptor a with Hybrid Peptide for Effective Cancer Therapy
نویسندگان
چکیده
Interleukin-4 receptor a (IL-4Ra) chain is highly expressed on the surface of various human solid tumors. We designed a novel hybrid peptide termed IL-4Ra–lytic peptide that targets the IL-4Ra chain. The IL-4Ra–lytic peptide contains a target moiety to bind to IL-4Ra and a cellular toxic lytic peptide that selectively kills cancer cells. The anticancer activity of the IL-4Ra–lytic peptide was evaluated in vitro and in vivo. It was found that the IL-4Ra–lytic peptide has cytotoxic activity in cancer cell lines expressing IL-4Ra, determined by quantitative real-time PCR. The IC50 ratios of the lytic peptide to the IL-4Ra–lytic peptide correlated well with the expression levels of IL-4Ra on cancer cells (r 1⁄4 0.80). In addition, IL-4Ra–lytic peptide administered either intratumoraly or intravenously significantly inhibited tumor growth in xenograft model of human pancreatic cancer (BXPC-3) in mice. These results indicate that the IL-4Ra–lytic peptide generated in this study has a potent and selective anticancer potential against IL-4Ra–positive solid cancers. Mol Cancer Ther; 11(1); 235–43. 2011 AACR.
منابع مشابه
Targeting interleukin-4 receptor α with hybrid peptide for effective cancer therapy.
Interleukin-4 receptor α (IL-4Rα) chain is highly expressed on the surface of various human solid tumors. We designed a novel hybrid peptide termed IL-4Rα-lytic peptide that targets the IL-4Rα chain. The IL-4Rα-lytic peptide contains a target moiety to bind to IL-4Rα and a cellular toxic lytic peptide that selectively kills cancer cells. The anticancer activity of the IL-4Rα-lytic peptide was e...
متن کاملPreclinical Development Targeting Interleukin-4 Receptor a with Hybrid Peptide for Effective Cancer Therapy
Interleukin-4 receptor a (IL-4Ra) chain is highly expressed on the surface of various human solid tumors. We designed a novel hybrid peptide termed IL-4Ra–lytic peptide that targets the IL-4Ra chain. The IL-4Ra–lytic peptide contains a target moiety to bind to IL-4Ra and a cellular toxic lytic peptide that selectively kills cancer cells. The anticancer activity of the IL-4Ra–lytic peptide was e...
متن کاملTargeting Interleukin-4 Receptor Alpha by Hybrid Peptide for Novel Biliary Tract Cancer Therapy
It is known that the interleukin-4 receptor α (IL-4R α ) is highly expressed on the surface of various human solid tumors. We previously designed novel IL-4R α -lytic hybrid peptide composed of binding peptide to IL-4R α and cell-lytic peptide and reported that the designed IL-4R α -lytic hybrid peptide exhibited cytotoxic and antitumor activity both in vitro and in vivo against the human pancr...
متن کاملIn silico prediction of B cell epitopes of the extracellular domain of insulin-like growth factor-1 receptor
The insulin-like growth factor-1 receptor (IGF-1R) is a transmembrane receptor with tyrosine kinase activity. The receptor plays a critical role in cancer. Using monoclonal antibodies (MAbs) against the IGF-1R, typically blocks ligand binding and enhances down-regulation of the cell-surface IGF-1R. Some MAbs such as cixutumumab are under clinical trial investigation. Targeting multiple distinct...
متن کاملIdentification of a Novel Tumor-Binding Peptide for Lung Cancer Through in-vitro Panning
Tumor-targeted therapies are playing growing roles in cancer research. The exploitation of these powerful therapeutic modalities largely depends on the discovery of tumor-targeting ligands. Phage display has proven a promising high throughput screening tool for the identification of novel specific peptides with high binding affinity to cancer cells. In the present study, we describe the use of ...
متن کامل